Bubs Australia jumps 45% on FDA approval for infant formula products
07/09/2026 01:08
BUZZ-Bubs Australia jumps 45% on FDA approval for infant formula products ** Shares of Bubs Australia BUB.AX rise as much as 45% to A$0.145 in early trade, posting their biggest intraday pct gain since end-May 2022
** Co gets permanent U.S. FDA approval for Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential infant formula products
** Shares hit highest level since January 14
** About 4.6 million shares change hands, 3.5 times the 30-day average
** YTD, BUB up 1.8%
(Reporting by Nichiket Sunil in Bengaluru)
Recent news on Bubs Australia
See all newsBubs Australia hits near two-month low as quarterly revenue declines
Bubs Australia shares set for 15% weekly gain on FDA approval for infant formula products
Bubs Australia extends rally after infant formulas get US FDA approval
Bubs Australia gets permanent FDA nod for infant formula sales in US, shares jump (updated)
Bubs Australia secures permanent FDA nod for infant formula sales in US, shares jump